# ZLAB catalysts: Zai Lab Ltd PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/zlab/catalysts

> Zai Lab Ltd (ZLAB) has 10 upcoming catalysts. The next is the Tecentriq® (atezolizumab) NDA/BLA submission, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ZLAB?

Zai Lab Ltd (ZLAB) has 10 upcoming catalysts. The next is the Tecentriq® (atezolizumab) NDA/BLA submission, 1H 2027. Press release filed with the SEC (EX-99): "•Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval." [Calendar and source filings](https://sec-api.dev/companies/zlab/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-053791, https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/companies/zlab/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Zai Lab Ltd |
| Ticker | ZLAB (Nasdaq) |
| SEC CIK | 1704292 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/zlab |

## Cash runway

Cash $559.7M as of 2026-09-30; quarterly burn $57.9M; about 29.0 months of runway at that rate (XBRL company facts, accession 0001628280-26-070521).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [COBENFY (cobenfy) FDA approval](https://sec-api.dev/pdufa/cobenfy) | ZLAB |  | completed, approved | "In September 2024, our partner BMS announced that the FDA had approved KarXT, under the brand name COBENFY™, for the treatment of adult patients with schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1704292/000162828024046824/zlab-20240930.htm)) |
| Oct 2024 | [Lua (lua) FDA approval](https://sec-api.dev/pdufa/lua) | ZLAB | metastatic NSCLC in October 2024 | completed, approved | "Zai Lab partner Novocure announced that TTFields was approved by the FDA under the brand name Optune Lua® for the treatment of metastatic NSCLC in October 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/zlab-20241112x8kex991.htm)) |
| Oct 2024 | [Zai Lab Ltd topline data readout](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed, positive | "-In October 2024, Zai Lab announced positive topline results from the Phase 3 bridging study evaluating the safety and efficacy of KarXT in schizophrenia in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/zlab-20241112x8kex991.htm)) |
| November 12, 2024 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., November 12, 2024 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828024046809/zlab-20241112x8kex991.htm)) |
| 1H 2025 | [AUGTYRO (repotrectinib) NDA/BLA submission](https://sec-api.dev/pdufa/repotrectinib) | ZLAB |  | scheduled | "Zai Lab plans to submit a supplemental NDA to the NMPA in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025008406/zlab-20250227x8kex991.htm)) |
| Jan 2025 | [Vedotin topline data readout](https://sec-api.dev/pdufa/vedotin) | ZLAB | previously treated recurrent or metastatic cervical cancer | completed, positive | "•Tisotumab Vedotin (Tissue Factor ADC): In January 2025, Zai Lab announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK® treatment for patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025008406/zlab-20250227x8kex991.htm)) |
| February 27, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., February 27, 2025 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025008406/zlab-20250227x8kex991.htm)) |
| Apr 2025 | [Zocilurtatug trial start](https://sec-api.dev/pdufa/zocilurtatug) | ZLAB |  | completed | "•ZL-1310 (DLL3 ADC): In April 2025, we initiated a global Phase I/II study in patients with selected solid neuroendocrine tumors, allowing us to evaluate its therapeutic potential beyond ES-SCLC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1704292/000162828025023411/zlab-20250331.htm)) |
| May 8, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025023410/zlab-202558x8kex991.htm)) |
| Jun 2025 | [Bemarituzumab topline data readout](https://sec-api.dev/pdufa/bemarituzumab) | ZLAB |  | completed, positive | "•Bemarituzumab: In June 2025, we announced positive topline results for the Phase III FORTITUDE-101 clinical trial evaluating bemarituzumab in FGFR2b positive 1L gastric cancer." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1704292/000162828025038548/zlab-20250630.htm)) |
| Jun 2025 | [Bemarituzumab interim data readout](https://sec-api.dev/pdufa/bemarituzumab) | ZLAB |  | completed, met | "•Bemarituzumab (FGFR2b): In June 2025, Zai Lab announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/zlab-202587x8kex991.htm)) |
| 2H 2025 | [Zocilurtatug trial start](https://sec-api.dev/pdufa/zocilurtatug) | ZLAB |  | scheduled | "-ZL-1310 (DLL3 ADC) is advancing rapidly, with upcoming ASCO 2025 data presentation in ES-SCLC; initiation of registrational study in ES-SCLC expected in the second half of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025023410/zlab-202558x8kex991.htm)) |
| August 7, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/zlab-202587x8kex991.htm)) |
| late 2025 | [ZL-1503 trial start](https://sec-api.dev/pdufa/zl-1503) | ZLAB |  | scheduled | "-Advancing other high-potential global programs, including initiation of a global Phase 1 study for ZL-1503 (IL-13xIL-31R bispecific antibody) and a planned IND submission for ZL-6201 (LRRC15 ADC) by year-end 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/zlab-2025116x8kex991.htm)) |
| Oct 2025 | [Zocilurtatug trial start](https://sec-api.dev/pdufa/zocilurtatug) | ZLAB |  | completed | "-In October 2025, Zai Lab initiated a global registrational study of zocilurtatug pelitecan monotherapy in second-line+ extensive-stage small cell lung cancer (ES-SCLC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/zlab-2025116x8kex991.htm)) |
| November 6, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/zlab-2025116x8kex991.htm)) |
| Dec 2025 | [Elegrobart trial start](https://sec-api.dev/pdufa/elegrobart) | ZLAB |  | completed | "•Elegrobart (anti-IGF-1R, subcutaneous): In December 2025, Zai Lab dosed the first patient in a registrational study in thyroid eye disease (TED) in mainland China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| Dec 2025 | [Povetacicept trial start](https://sec-api.dev/pdufa/povetacicept) | ZLAB |  | completed | "•Povetacicept (APRIL/BAFF): In December 2025, Zai Lab joined the global pivotal Phase 2/3 OLYMPUS study in primary membranous nephropathy (pMN) and dosed the first patient in mainland China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| Dec 2025 | [ZL-1503 trial start](https://sec-api.dev/pdufa/zl-1503) | ZLAB |  | completed | "•ZL-1503 (IL-13/IL-31Rα): In December 2025, Zai Lab dosed the first participant in a global Phase 1/1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503 for the treatment of AD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| December 16, 2025 | [Zl-1102 1% w/w gel bid for 16 weeks primary completion](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) | ZLAB | Plaque Psoriasis | withdrawn | "NCT06380907 (A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Zai Lab (Hong Kong), Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380907)) |
| Jan 2026 | [ZL-6201 FDA approval](https://sec-api.dev/pdufa/zl-6201) | ZLAB | certain solid tumors | completed, approved | "•ZL-6201, a novel potential first-in-class ADC targeting LRRC15, using our internally developed anti-LRRC15 antibody, for the treatment of certain solid tumors, for which the FDA approved the IND in January 2026 and a global Phase 1 study was initiated in the first quarter of 2026;" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm)) |
| Jan 2026 | [Zai Lab Ltd NDA/BLA acceptance](https://sec-api.dev/companies/zlab/catalysts) | ZLAB | with acetylcholine receptor antibody | completed | "-Seronegative generalized myasthenia gravis (sn-gMG): In January 2026, the FDA accepted for Priority Review a supplemental Biologics License Application (sBLA) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) sn-gMG, with a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| 1H 2026 | [Tecentriq® (atezolizumab) trial start](https://sec-api.dev/pdufa/atezolizumab) | ZLAB |  | scheduled | "Zai Lab also plans to initiate a Phase 1 study to explore zoci in a novel combination in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| 2026 | [ZL-1503 interim data readout](https://sec-api.dev/pdufa/zl-1503) | ZLAB |  | scheduled | "-ZL-1503 (IL-13/IL-31Rα) demonstrated rapid, durable dual-pathway activity in preclinical data presented at IMMUNOLOGY2026, supporting less frequent dosing and broad potential across atopic diseases, including asthma; Phase 1/1b study underway with initial data expected in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-202657x8kex991.htm)) |
| Jan 2026 | [IMDELLTRA® (tarlatamab) trial start](https://sec-api.dev/pdufa/tarlatamab) | ZLAB |  | completed | "-Extrapulmonary NECs: In January 2026, Zai Lab dosed the first patient in the global Phase 2 portion of its ongoing Phase 1b/2 study in NECs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| February 26, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., February 26, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| Mar 2026 | [Povetacicept interim data readout](https://sec-api.dev/pdufa/povetacicept) | ZLAB |  | completed, positive | "-IgA nephropathy (IgAN): In March 2026, Zai Lab partner Vertex announced positive data from a pre-specified Week 36 interim analysis of the global Phase 3 RAINIER trial of pove in IgA nephropathy (IgAN)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-202657x8kex991.htm)) |
| May 7, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., May 7, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-202657x8kex991.htm)) |
| May 10, 2026 | [Zai Lab Ltd PDUFA date](https://sec-api.dev/companies/zlab/catalysts) | ZLAB | with acetylcholine receptor antibody | scheduled | "-Seronegative generalized myasthenia gravis (sn-gMG): In January 2026, the FDA accepted for Priority Review a supplemental Biologics License Application (sBLA) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) sn-gMG, with a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| Jun 2026 | [Povetacicept NDA/BLA acceptance](https://sec-api.dev/pdufa/povetacicept) | ZLAB | immunoglobulin A nephropathy | completed | "•Povetacicept (pove, APRIL/BAFF): In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm)) |
| Aug 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ZLAB | autoimmune myositis | completed, positive | "•Efgartigimod (FcRn): In August 2026, we and our partner argenx announced positive topline results from the Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070521/zlab-20260930.htm)) |
| Aug 2026 | [ZL-1503 trial start](https://sec-api.dev/pdufa/zl-1503) | ZLAB |  | completed | "In August 2026, we initiated enrollment for a global Phase 1 intravenous-to-subcutaneous bioavailability bridging study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070521/zlab-20260930.htm)) |
| August 6, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., August 6, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2026, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm)) |
| November 5, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., November 5, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-2026115x8kex991.htm)) |
| 1H 2027 | [Tecentriq® (atezolizumab) NDA/BLA submission](https://sec-api.dev/pdufa/atezolizumab) | ZLAB |  | scheduled | "•Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm)) |
| 1H 2027 | [Zai Lab Ltd topline data readout](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | scheduled | "Based on feedback from the U.S. Food and Drug Administration (FDA), Zai Lab will pursue a potential accelerated approval pathway based on this single-arm expansion study with topline data expected in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-2026115x8kex991.htm)) |
| 1H 2027 | [ZL-1503 interim data readout](https://sec-api.dev/pdufa/zl-1503) | ZLAB | AD with initial clinical data | scheduled | "•Complete enrollment in the multiple ascending dose (MAD) portion of the Phase 1/1b study in patients with AD with initial clinical data from the MAD portion expected in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-2026115x8kex991.htm)) |
| 1H 2027 | [Tecentriq® (atezolizumab) interim data readout](https://sec-api.dev/pdufa/atezolizumab) | ZLAB |  | scheduled | "•Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm)) |
| Mar to Jun 2027 | [Zl-1109 (vrdn-003) topline data readout](https://sec-api.dev/pdufa/zl-1109-vrdn-003) | ZLAB | Thyroid Eye Disease (TED) | scheduled | "NCT07211776 (A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-14 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211776)) |
| March 2027 | [Zl-1109 (vrdn-003) primary completion](https://sec-api.dev/pdufa/zl-1109-vrdn-003) | ZLAB | Thyroid Eye Disease (TED) | scheduled | "NCT07211776 (A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-14 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211776)) |
| Jun to Sep 2028 | [ZL-1310 topline data readout](https://sec-api.dev/pdufa/zl-1310) | ZLAB | Small-cell Lung Cancer | scheduled | "NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218146)) |
| June 2028 | [ZL-1310 primary completion](https://sec-api.dev/pdufa/zl-1310) | ZLAB | Small-cell Lung Cancer | scheduled | "NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218146)) |
| Jun to Sep 2030 | [Zl-1310 in combination with atezolizumab or durvalumab topline data readout](https://sec-api.dev/pdufa/zl-1310-in-combination-with-atezolizumab-or-durvalumab) | ZLAB | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT07796100 (A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07796100)) |
| June 2030 | [Zl-1310 in combination with atezolizumab or durvalumab primary completion](https://sec-api.dev/pdufa/zl-1310-in-combination-with-atezolizumab-or-durvalumab) | ZLAB | Extensive-Stage Small Cell Lung Cancer | scheduled | "NCT07796100 (A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor Zai Lab (Shanghai) Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07796100)) |

## Drugs

- [COBENFY (cobenfy)](https://sec-api.dev/pdufa/cobenfy): 
- [Lua (lua)](https://sec-api.dev/pdufa/lua): metastatic nsclc in october 2024
- [Vedotin](https://sec-api.dev/pdufa/vedotin): previously treated recurrent or metastatic cervical cancer
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks): Plaque Psoriasis
- [Zl-1109 (vrdn-003)](https://sec-api.dev/pdufa/zl-1109-vrdn-003): Thyroid Eye Disease (TED)
- [ZL-1310](https://sec-api.dev/pdufa/zl-1310): Small-cell Lung Cancer
- [Zl-1310 in combination with atezolizumab or durvalumab](https://sec-api.dev/pdufa/zl-1310-in-combination-with-atezolizumab-or-durvalumab): Extensive-Stage Small Cell Lung Cancer
- [ZL-1503](https://sec-api.dev/pdufa/zl-1503): ad with initial clinical data
- [ZL-6201](https://sec-api.dev/pdufa/zl-6201): certain solid tumors
- [Zocilurtatug](https://sec-api.dev/pdufa/zocilurtatug): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/zlab/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZLAB catalysts: Zai Lab Ltd PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/zlab/catalysts

```bibtex
@misc{secapidev_companies_zlab_catalysts_20261116,
  title        = {ZLAB catalysts: Zai Lab Ltd PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/zlab/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_zlab_catalysts_20261116","title":"ZLAB catalysts: Zai Lab Ltd PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/zlab/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
